RxDoctor Payments Data

Andreas Wolf, MD

Interventional Cardiology · Sonora, CANPI 1073519336

Payments from drug & device makers

$4,983in general payments, 2019–2025

Across 255 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$733
  • Abbott$599
  • Johnson & Johnson$590
  • AstraZeneca$511
  • Medtronic$489
  • Amgen$444
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,969100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,983 in reported general payments places this provider in the 30th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$132,449
Medicare patients
1,087
Services billed
2,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$119,254
EntrestoSacubitril/Valsartan42$67,666
JardianceEmpagliflozin29$34,349
FarxigaDapagliflozin Propanediol19$25,790
XareltoRivaroxaban14$18,706
BrilintaTicagrelor12$11,429
Repatha SureclickEvolocumab11$8,694
Ezetimibe49$2,117
Metoprolol Succinate105$1,770
Rosuvastatin Calcium90$1,406
Valsartan29$1,135
Losartan Potassium77$1,033
Atorvastatin Calcium98$1,000
Amlodipine Besylate105$728
ClopidogrelClopidogrel Bisulfate49$691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$119,25496 claims
NovartisEntresto$190$67,66642 claims
AstraZenecaFarxiga, Brilinta$511$37,22031 claims
Boehringer IngelheimJardiance$23$34,34929 claims
Johnson & JohnsonXarelto$590$18,70614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Sonora

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →